Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorXingshun Qi

About this trial

Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.

Eligibility criteria

Qualifiers

Patients with liver cirrhosis;

Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and/or hematochezia;

Adults (age≥18 years old).

Disqualifiers

Components of Child-Pugh, MELD, and CAGIB scores are not available;

In-hospital outcomes are not evaluable.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

23
Brazil
São Paulo State University (UNESP), Botucatu Medical School São PauloSão Paulo, Brazil
China
Beijing Youan Hospital, Capital Medical University BeijingBeijing Municipality, China
The Seventh Medical Center of Chinese PLA General Hospital BeijingBeijing Municipality, China
First Affiliated Hospital of Fujian Medical University FuzhouFujian, China

Sponsors and collaborators

Xingshun Qi

Lead sponsor

General Hospital of Shenyang Military Region

Sponsor institution